CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.152
https://www.valueinhealthjournal.com/article/S1098-3015(22)02356-7/fulltext
Title :
CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02356-7&doi=10.1016/j.jval.2022.09.152
First page :
Section Title :
Open access? :
No
Section Order :
11130